Bay-12-9566. Oncolytic, antiarthritic, matrix metalloproteinase inhibitor

Drugs of the Future

Volumn 24, Issue 1, 1999, Pages 16-21

  Sorbera, L A ^a   Graul, A ^a   Silvestre, J ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4' CHLOROBIPHENYL 4 YL) 4 OXO (PHENYLSULFANYLMETHYL)BUTYRIC ACID; ANTINEOPLASTIC AGENT; ANTIRHEUMATIC AGENT; BATIMASTAT; CGS 27023A; CIPEMASTAT; ILOMASTAT; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; PRINOMASTAT; REBIMASTAT; TANOMASTAT; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTHRITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; OSTEOARTHRITIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RHEUMATOID ARTHRITIS; SOLID TUMOR; THROMBOCYTOPENIA;

EID: 0032997033     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1999.024.01.483363     Document Type: Article

References (38)

1. Kluender, H.C.E., Benz, G.H.H.H., Britelli, D.R. et al. (Bayer Corp.). Substd. 4-biarylbutyric or 5-biarylpentanoic acids and derivs. as matrix metalloprotease inhibitors. EP 790974, JP 98509146, US 5789434, US 5859047, WO 9615096.
2. Woesner, J.F. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991, 5: 2145-54.
3. Walakovits, L.A., Bhardwaj, N., Gallick, G.S., Lark, M.W. Detection of high levels of stromelysin and collagenase in synovial fluid in patients with rheumatoid arthritis and post traumatic knee injury. Arthritis Rheum 1992, 35: 35-42.
4. Pyke, C., Ralkiaer, E., Huhtala, P., Hurskeinen, T., Dano, K., Tryggvason, K. Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization. Cancer Res 1992, 52: 1336-41.
5. Overall, C.M., Wiebkin, O.W., Thonard, J.C. Demonstration of tissue collagenase activity in vivo and its relationship to inflammation severity in human gingiva. J Peridontal Res 1987, 22: 81-8.
6. Gijbels, K., Galardy, R.E., Steinman, L. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteinases. J Clin Invest 1994, 94: 2177-82.
7. Rasmussen, H.S., McCann, P.P. Matrix metalloproteinase inhibitors as a novel anticancer strategy: A review with special focus on batimastat and marimastat. Pharmacol Ther 1997, 75: 69-75.
8. Bramhall, S.R. The matrix metalloproteinases and their inhibitors in pancreatic cancer. Int J Pancreatol 1997, 21: 1-12.
9. Hibner, B., Card, A., Flynn, C., Casazza, A.M., Taraboletti, G., Rieppi, M., Giavazzi, R. BAY 12-9566, a novel, biphenyl matrix metalloproteinase inhibitor, demonstrates anti-invasive and anti-angiogenic properties. Proc Am Assoc Cancer Res 1998, 39: Abst 2063.
10. Gatto, C., Rieppi, M., Borsotti, P., Drudis, T., Vergani, V., Hibner, B., Casazza, A.M., Taraboletti, G., Giavazzi, R. Anti-angiogenic activity of BAY 12-9566, an inhibitor of matrix metalloproteinases. 10th NCI-EORTC Symp New Drugs Cancer Ther (June 16-19, Amsterdam) 1998, Abst 281.
11. Hibner, B., Bull, C., Flynn, C., Eberwein, D., Garrison, T.A., Casazza, A., Carter, C., Gibson, N. Activity of the matrix metalloproteinase inhibitor BAY 12-9566 against murine subcutaneous and metastatic in vivo models. 70th NCI-EORTC Symp New Drugs Cancer Ther (June 16-19, Amsterdam) 1998, Abst 283.
12. Bull, C., Flynn, C., Eberwein, D., Casazza, A.M., Carter, C.A., Hibner, B. Activity of the biphenyl matrix metalloproteinase inhibitor BAY 12-9566 in murine in vivo models. Proc Am Assoc Cancer Res 1998, 39: Abst 2062.
13. Flynn, C., Bull, C., Matherne, C., Eberwein, D., Gibson, N., Hibner, B. Anti-invasive and anti-metastatic activity of the novel MMP inhibitor BAY 12-9566 in subcutaneous and orthotopic models using the human colon carcinoma, HCT116. 10th NCI-EORTC Symp New Drugs Cancer Ther (June 16-19, Amsterdam) 1998, Abst 284.
14. Flynn, C., Bull, C., Eberwein, D., Matherne, C., Hibner, B. Anti-metastatic activity of BAY 12-9566 in a human colon carcinoma HCT116 orthotopic model. Proc Am Assoc Cancer Res 1998,39: Abst 2057.
15. Nozaki, S., Sissons, S., Casazza, A.M., Sledge, G.W. Jr. Inhibition of human breast cancer regrowth and pulmonary metastases by BAY 12-9566 in athymic mice. Proc Am Assoc Cancer Res 1998, 39: Abst 2053.
16. Chau, T., Jolly, G., Plym, M.-J., McHugh, M., Bortolon, E., Wakefield, J., Gianpaolo-Ostravage, C., Maniglia, C. Inhibition of articular cartilage degradation in dog and guinea pig models of osteoarthritis by the stromelysin inhibitor, BAY 12-9566. 62nd Natl Meet Am Coll Rheumatol (Nov 8-12, San Diego) 1998, Abst 1605.
17. Clemens, G.R., Detzer, K., Bomhard, E., von Keutz, E. Preclinical drug safety profile for the antimetastatic matrix metalloproteinase inhibitory agent BAY 12-9566. 10th NCI-EORTC Symp New Drugs Cancer Ther (June 16-19, Amsterdam) 1998, Abst 282.
18. Sundaresan, P.R., Shah, A., Woodruff, M., Kelly, N., Heller, A.H. Safety and pharmacokinetics (PK) of BAY 12-9566, a metalloproteinase (MMP) inhibitor in middle-aged and elderly subjects. Clin Pharmacol Ther 1998, 63(2): Abst PI-128.
19. Sundaresan, P.R., Shah, A., Heller, A.M. Penetration of BAY 12-9566 in synovial fluid and effect of age and gender on the pharmacokinetics (PK) of BAY 12-9566. Clin Pharmacol Ther 1998, 63(2): Abst PI-129.
20. Shah, A., Sundaresan, P., Humphrey, R., Heller, A.H. Comparative pharmacokinetics (PK) of BAY 12-9566, a metalloproteinase (MMP) inhibitor, in healthy volunteers and cancer patients. Proc Am Assoc Cancer Res 1998, 39: Abst 3547.
21. Hirte, H., Goel, R., Major, P., Waterfield, B., Holohan, S., Bennett, K., Shah, A., Elias, I., Seymour, L. Pharmacokinetics of BAY 12-9566: Early results of a Canadian phase I dose escalation study in cancer patients. Proc Am Assoc Cancer Res 1998, 39: Abst 2484.
22. Hirte, H., Goel, R., Bennett, K., Elias, I., Shah, A., Seymour, L. Phase I study of the matrix metalloprotease inhibitor (MMPI) BAY 12-9566 in patients with advanced cancer. 10th NCI-EORTC Symp New Drugs Cancer Ther (June 16-19, Amsterdam) 1998, Abst 286.
23. Goel, R., Hirte, H., Shah, A., Major, P., Waterfield, B., Holohan, S., Bennett, K., Elias, I., Seymour, L. Phase I study of the metalloproteinase inhibitor Bayer 12-9566. Proc Am Soc Clin Oncol 1998, 17: Abst 840.
24. Erlichman, C., Adjei, A., Alberts, S., Sloan, J., Goldberg, R., Pilot, H., Rubin, J. Phase I study of BAY 12-9566 - A matrix metalloproteinase inhibitor (MMPI). Proc Am Soc Clin Oncol 1998, 17: Abst 837.
25. Rowinsky, E., Hammond, L., Aylesworth, C. et al. Prolonged administration of BAY 12-9566, an oral non-peptidic biphenyl matrix: A phase I and pharmacologic study. 10th NCI-EORTC Symp New Drugs Cancer Ther (June 16-19, Amsterdam) 1998, Abst 287.
26. Rowinsky, E., Hammond, L., Aylesworth, C. et al. Prolonged administration of Bay 12-9566, an oral non peptidic biphenyl matrix metalloproteinase (MMP) inhibitor: A phase I and pharmacokinetic (PK) study. Proc Am Soc Clin Oncol 1998, 17: Abst 836.
27. Grochow, L.B. Preclinical and clinical pharmacology of matrix metalloproteinase inhibitors (MMPIs). 10th NCI-EORTC Symp New Drugs Cancer Ther (June 16-19, Amsterdam) 1998, Abst 034.
28. Grochow, L., O'Reilly, S., Humphrey, R. et al. Phase I and pharmacokinetic study of the matrix metalloproteinase inhibitor (MMPI), BAY12-9566. Proc Am Soc Clin Oncol 1998, 17: Abst 822.
29. Seymour, L., Hirte, H., Goel, R., Moore, M., Elias, I., Kumor, K., Humphrey, R. Planned and completed NCIC CTG trials with BAY 12-9566, a novel metalloproteinase inhibitor (MMPI). 10th NCI-EORTC Symp New Drugs Cancer Ther (June 16-19, Amsterdam) 1998, Abst 288.
30. Rothenberg, M.L, Nelson, A.R., Hande, K.R. New drugs on the horizon: Matrix metalloproteinase inhibitors. Oncologist 1998, 3:271-4.
31. Beckett, R.P., Crimmin, M.J., Galloway, W.A. Matrix metalloproteinase inhibitors in the treatment oi rheumatoid arthritis and cancer. 205th ACS Natl Meet (March 28-April 2, Denver) 1993, Abst MEDI 147.
32. MacPherson, L.J., Bayburt E.K., Capparelli, M.P. et al. Discovery of CGS 27023A, a non-peptidic, potent, and orally active stmmelysin inhibitor that blocks cartilage degradation in rabbits. J Med Chem 1997, 40: 2525-32.
33. Ganu, V. et al. Biochemical and pharmacological profile of a nonpeptidic orally active inhibitor of matrix metalloproteinases. Osteoarthr Cartil 1994, 2(Suppl. 1): Abst 19.
34. O'Byrne, E. et al. Chondroprotective activity of an MMP inhibitor in animal models of osteoarthritis. IBC 5th Int Conf Arthritis Adv Diagn Treat (Nov 28-29, New Orleans) 1995.
35. Brown, P. et al. Matrix metalloproteinase inhibition: A novel approach to the treatment of cancer. Ann Oncol 1996, 7(Suppl. 5): Abst 39.
36. Broadhurst, M.J. et al. Design and synthesis of the cartilage protective agent (CPA, Ro 32-3555). Bioorg Med Chem Lett 1997, 7: 2299.
37. Lewis, E.J., Bishop, J., Bottomley, K.M. et al. Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo. Br J Pharmacol 1997, 121:540-6.
38. Gijbels, K. Matrix metalloproteinase inhibitors. IBC Conf Adv Underst Treat Mult Scler (June 17-18, San Francisco) 1996.